Igc Pharma Inc (IGC)

$0.34 0.00 (N/A)
Market Cap 26.33M
Revenue (ttm) 1.35M
Net Income (ttm) -13.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -962.96%
Debt to Equity Ratio 0.02
Volume 139,000
Avg Vol 400,926
Day's Range N/A - N/A
Shares Out 77.45M
Stochastic %K 51%
Beta 1.32
Analysts Sell
Price Target $3.75

Latest News on IGC

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 13, 2025, 8:30 AM EST - 5 days ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Jan 8, 2025, 8:30 AM EST - 10 days ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 19, 2024, 7:00 PM EST - 4 weeks ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Dec 2, 2024, 8:30 AM EST - 6 weeks ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 25, 2024, 8:30 AM EST - 7 weeks ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 14, 2024, 8:30 AM EST - 2 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Nov 6, 2024, 8:30 AM EST - 2 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 17, 2024, 8:30 AM EDT - 3 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Oct 3, 2024, 9:00 AM EDT - 3 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 18, 2024, 8:00 AM EDT - 4 months ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Sep 4, 2024, 8:00 AM EDT - 4 months ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma Reports First Quarter Fiscal 2025 Results

Aug 8, 2024, 9:30 PM EDT - 5 months ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 18, 2024, 9:00 AM EDT - 6 months ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jul 9, 2024, 9:10 AM EDT - 6 months ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 25, 2024, 9:00 AM EDT - 7 months ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

Jun 10, 2024, 9:00 AM EDT - 7 months ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 28, 2024, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma to Attend BIO International Convention 2024

May 21, 2024, 2:00 PM EDT - 8 months ago

IGC Pharma to Attend BIO International Convention 2024

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 16, 2024, 7:00 AM EDT - 9 months ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

IGC Pharma Adds Advisor in Artificial Intelligence

Apr 9, 2024, 9:00 AM EDT - 10 months ago

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 26, 2024, 3:00 PM EDT - 10 months ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 11:00 AM EDT - 10 months ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 20, 2024, 7:00 AM EDT - 10 months ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

Mar 12, 2024, 3:00 PM EDT - 11 months ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Feb 23, 2024, 12:01 PM EST - 11 months ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Feb 16, 2024, 7:05 PM EST - 1 year ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Feb 1, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

Jan 23, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

Jan 17, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

Dec 19, 2023, 9:20 AM EST - 1 year ago

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

Dec 13, 2023, 9:30 AM EST - 1 year ago

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

Dec 6, 2023, 8:30 AM EST - 1 year ago

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

Nov 21, 2023, 8:30 AM EST - 1 year ago

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

IGC Pharma Reports Second Quarter Fiscal 2024 Results

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

Oct 19, 2023, 3:30 PM EDT - 1 year ago

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials

Aug 14, 2023, 8:30 AM EDT - 1 year ago

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

Aug 2, 2023, 8:30 AM EDT - 1 year ago

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

Jul 18, 2023, 5:22 AM EDT - 1 year ago

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

Jul 7, 2023, 9:15 AM EDT - 1 year ago

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

Jul 6, 2023, 7:46 AM EDT - 1 year ago

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

IGC Pharma Receives Notice of Allowance for Patent on Seizures

Jun 6, 2023, 9:20 AM EDT - 1 year ago

IGC Pharma Receives Notice of Allowance for Patent on Seizures

IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award

Jun 5, 2023, 8:30 AM EDT - 1 year ago

IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award

IGC Pharma to Present at LD Micro Invitational XIII

May 18, 2023, 8:30 AM EDT - 1 year ago

IGC Pharma to Present at LD Micro Invitational XIII

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

Apr 18, 2023, 8:30 AM EDT - 1 year ago

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

Mar 20, 2023, 8:45 AM EDT - 1 year ago

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

Feb 14, 2023, 7:41 PM EST - 2 years ago

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

Feb 8, 2023, 8:30 AM EST - 2 years ago

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

LTK Releases 2023 State of Creator Guided Shopping Trends Report

Jan 18, 2023, 3:00 PM EST - 2 years ago

LTK Releases 2023 State of Creator Guided Shopping Trends Report

IGC Receives No Objection Letter from Health Canada

Jan 4, 2023, 8:00 AM EST - 2 years ago

IGC Receives No Objection Letter from Health Canada